Actively Recruiting
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
Led by Saint-Louis Hospital, Paris, France · Updated on 2026-04-24
575
Participants Needed
17
Research Sites
1355 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Crohn's disease (CD), a chronic inflammatory process in intestinal segments leads to tissue damage. More than two thirds of CD patients need intestinal resection. Symptomatic clinical recurrence occurs in 60% by 10 years. The principal factors affecting postoperative recurrence are active smoking, penetrating disease, perianal lesions history, prior intestinal resection, small bowel resection extent, and prophylaxis treatment absence. Ileocolonoscopy within one year of surgery can predict clinical recurrence risk. Different therapies are proposed after surgery, to prevent post-operative recurrence : Thiopurines, 6-mercaptopurine (positive for clinical and endoscopic postoperative recurrence prevention), Anti-tumour necrosis factor therapy (anti-TNF), the most effective therapy. Intestinal microbiota acts as a central factor in the CD pathogenesis, and fecal stream role is clearly shown. Various changes in luminal flora with a possible link to local inflammation was also demonstrated. Bacteria associated with postoperative recurrence could be more pathogenic as adherent invasive E coli (AIEC), which could be a pathogen in CD through several mechanisms including increased mucosal colonization, adherence, replication and induction of TNF secretion. Alternatively, postoperative CD recurrence could be linked to a protective commensal species lack, such as Faecalibacterium prausnitzii. Microscopic inflammation occurs as early as 8 days after anastomosis in the neoterminal ileum mucosa. IL6, IL10 and TGFb levels, measured in neoterminal ileum early after surgery are associated with different rates of postoperative recurrence. It suggests cytokines implication in postoperative recurrence. T cells are major players in the intestinal immune response. The presence at time of surgery and persistence of disease inducing T cell clonal expansions could play an important role in post-operative recurrence. The main objective is to define a classification of ileal Crohn's Disease based on data integration on a large cohort of patients.
CONDITIONS
Official Title
Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide informed consent before any study activities
- Diagnosed with Crohn's disease based on clinical, radiologic, endoscopic, or histological evidence
- Men and women aged 18 years or older
- Scheduled for ileocecal resection surgery
You will not qualify if you...
- History of dysplasia or cancer in the ileum or colon
- Unable or unwilling to follow study procedures
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
SART Tilman Hospital
Liège, Belgium
Actively Recruiting
2
Amiens Hospital
Amiens, France, 80054
Actively Recruiting
3
Haut-levêque Hospital
Bordeaux, France, 33
Active, Not Recruiting
4
Clermont-Ferrand Hospital
Clermont-Ferrand, France, 63003
Actively Recruiting
5
Beaujon Hospital
Clichy, France, 92110
Actively Recruiting
6
Henri Mondor Hospital
Créteil, France
Actively Recruiting
7
Kremlin-Bicêtre Hospital
Le Kremlin-Bicêtre, France
Actively Recruiting
8
Lille Hospital
Lille, France, 59037
Actively Recruiting
9
Hôpital Nord, CHU Marseille
Marseille, France
Actively Recruiting
10
Montpellier Hospital
Montpellier, France
Actively Recruiting
11
Brabois Hospital
Nancy, France
Actively Recruiting
12
Nantes Hospital
Nantes, France, 44093
Actively Recruiting
13
Archet 2 Hospital
Nice, France, 06202
Actively Recruiting
14
Saint Louis Hospital
Paris, France, 75010
Actively Recruiting
15
Saint Antoine Hospital
Paris, France, 75012
Actively Recruiting
16
South Lyon Hospital
Pierre-Bénite, France, 69495
Actively Recruiting
17
Strasbourg Hospital
Strasbourg, France
Active, Not Recruiting
Research Team
M
Matthieu ALLEZ, Pr
CONTACT
P
Philippe SEKSIK, Pr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here